Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
Public ClinicalTrials.gov record NCT01266525. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Primary Objective: \- To demonstrate the efficacy of at least one dose of SAR110894 (H3 receptor antagonist) in comparison to placebo on cognitive performance in patients with mild to moderate Alzheimer's disease (AD) while on stable donepezil therapy Secondary Objectives: * To explore the effect of SAR110894 on functional impairment, global clinical status and behavioral disturbances; * To assess the safety/tolerability of SAR110894; * To assess pharmacokinetic (PK) of SAR110894 and concentrations of donepezil; * To explore caregiver time consumption and distress changes.
Study identification
- NCT ID
- NCT01266525
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 291 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 55 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 2011 (Type not available)
- Primary completion
- Jan 2013 (Actual)
- Completion
- Jan 2013 (Actual)
- Last update posted
- Mar 14, 2016
2011 – 2013
United States locations
- U.S. sites
- 27
- U.S. states
- 15
- U.S. cities
- 27
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Investigational Site Number 840041 | Gilbert | Arizona | 85234 | — |
| Investigational Site Number 840032 | Phoenix | Arizona | 85060 | — |
| Investigational Site Number 840024 | Costa Mesa | California | 92626 | — |
| Investigational Site Number 840013 | Fresno | California | 93720 | — |
| Investigational Site Number 840030 | La Jolla | California | 92037 | — |
| Investigational Site Number 840001 | Redlands | California | 92374 | — |
| Investigational Site Number 840002 | Santa Ana | California | 92705 | — |
| Investigational Site Number 840026 | Sherman Oaks | California | 91403 | — |
| Investigational Site Number 840034 | Darien | Connecticut | 06820 | — |
| Investigational Site Number 840003 | Delray Beach | Florida | 33445 | — |
| Investigational Site Number 840015 | Hialeah | Florida | 33016 | — |
| Investigational Site Number 840004 | Jacksonville | Florida | 32216 | — |
| Investigational Site Number 840006 | Miami | Florida | 33155 | — |
| Investigational Site Number 840012 | Orlando | Florida | 32806 | — |
| Investigational Site Number 840011 | Tampa | Florida | 33609-4052 | — |
| Investigational Site Number 840005 | West Palm Beach | Florida | 33407 | — |
| Investigational Site Number 840008 | Baton Rouge | Louisiana | 70808 | — |
| Investigational Site Number 840025 | Quincy | Massachusetts | 02169 | — |
| Investigational Site Number 840009 | Hattiesburg | Mississippi | 39401 | — |
| Investigational Site Number 840040 | Eatontown | New Jersey | 07724 | — |
| Investigational Site Number 840018 | Cedarhurst | New York | 11516 | — |
| Investigational Site Number 840039 | Charlotte | North Carolina | 28204 | — |
| Investigational Site Number 840037 | Tulsa | Oklahoma | 74104 | — |
| Investigational Site Number 840014 | Franklin | Tennessee | 37067 | — |
| Investigational Site Number 840038 | Austin | Texas | 78757 | — |
| Investigational Site Number 840021 | Bennington | Vermont | 05201 | — |
| Investigational Site Number 840031 | Williamsburg | Virginia | 23185 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 55 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01266525, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 14, 2016 · Synced Oct 30, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01266525 live on ClinicalTrials.gov.